These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8845497)

  • 1. The importance of dose and schedule in cancer chemotherapy: haematological cancer.
    Sweetenham JW
    Anticancer Drugs; 1995 Oct; 6 Suppl 5():7-15. PubMed ID: 8845497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma: a dose-escalation, open-label, pharmacokinetic, phase 1 study.
    Amorim S; Stathis A; Gleeson M; Iyengar S; Magarotto V; Leleu X; Morschhauser F; Karlin L; Broussais F; Rezai K; Herait P; Kahatt C; Lokiec F; Salles G; Facon T; Palumbo A; Cunningham D; Zucca E; Thieblemont C
    Lancet Haematol; 2016 Apr; 3(4):e196-204. PubMed ID: 27063978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of dose and schedule in chemotherapy for small cell lung cancer.
    Ranson M; Thatcher N
    Anticancer Drugs; 1995 Oct; 6 Suppl 5():53-63. PubMed ID: 8845495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [What is reliable in the therapy of hematologic diseases? I. Hemoblastosis and malignant lymphoproliferative diseases].
    Havemann K; Schmidt M; Malchow H; Sodomann CP
    Internist (Berl); 1970 Dec; 11(12):441-9. PubMed ID: 4993105
    [No Abstract]   [Full Text] [Related]  

  • 5. Cladribine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in haematological malignancies.
    Bryson HM; Sorkin EM
    Drugs; 1993 Nov; 46(5):872-94. PubMed ID: 7507037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The treatment of chronic hemoblastosis with new cytostatic agents].
    Quattrin N
    Minerva Med; 1966 Mar; 57(25):1141-3. PubMed ID: 5932017
    [No Abstract]   [Full Text] [Related]  

  • 7. Management of haematological malignancy in pregnancy.
    El-Hemaidi I; Robinson SE
    Best Pract Res Clin Obstet Gynaecol; 2012 Feb; 26(1):149-60. PubMed ID: 22119057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apoptosis as a tool for therapeutic agents in haematological diseases.
    Alenzi FQ; Wyse RK; Altamimi WG
    Expert Opin Biol Ther; 2004 Mar; 4(3):407-20. PubMed ID: 15006734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and risk factors for severe COVID-19 in patients with haematological disorders receiving chemo- or immunotherapy.
    Fox TA; Troy-Barnes E; Kirkwood AA; Chan WY; Day JW; Chavda SJ; Kumar EA; David K; Tomkins O; Sanchez E; Scully M; Khwaja A; Lambert J; Singer M; Roddie C; Morris EC; Yong KL; Thomson KJ; Ardeshna KM
    Br J Haematol; 2020 Oct; 191(2):194-206. PubMed ID: 32678948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose optimisation and dose intensification in malignant lymphoma.
    Linch DC
    Eur J Cancer; 1994; 30A(1):122-5. PubMed ID: 8142153
    [No Abstract]   [Full Text] [Related]  

  • 12. [Phase II study of methyl 6-[3-(2-chloroethyl)-3-nitrosoureido]-6-deoxy-alpha-D-glucopyranoside (MCNU)].
    Tanaka I; Kobayashi T; Shirakawa S; Ikeda Y; Kobayashi M; Yamagata K; Ohta K; Ohno R; Yamada H; Yamada K
    Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):493-8. PubMed ID: 3859248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term perspective of hematologic malignancies.
    Cheson BD
    Trans Assoc Life Insur Med Dir Am; 1988; 71():198-220. PubMed ID: 3285568
    [No Abstract]   [Full Text] [Related]  

  • 14. Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement.
    Rodenhuis S; Richel DJ; van der Wall E; Schornagel JH; Baars JW; Koning CC; Peterse JL; Borger JH; Nooijen WJ; Bakx R; Dalesio O; Rutgers E
    Lancet; 1998 Aug; 352(9127):515-21. PubMed ID: 9716055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dose intensity in cancer chemotherapy (including high dose chemotherapy)].
    Ariyoshi Y; Ogawa M
    Gan To Kagaku Ryoho; 1994 Dec; 21(16):2699-707. PubMed ID: 7993104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose chemotherapy in breast cancer.
    Lake DE; Hudis CA
    Drugs; 2004; 64(17):1851-60. PubMed ID: 15329034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy dose intensity facilitated by use of lenograstim--implications for quality of life and survival.
    Gisselbrecht C
    Eur J Cancer; 1994; 30A Suppl 3():S30-3. PubMed ID: 7535070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [m-TOR inhibitors: biology and use in the treatment of haematological diseases].
    Balsat M; Cornillon J
    Bull Cancer; 2011 Aug; 98(8):935-43. PubMed ID: 21827982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
    Kimby E; Nygren P; Glimelius B;
    Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Rituximab. A monoclonal CD20 antibody--hematological indications and possible treatments for immunoinflammatory diseases].
    Hansen PB; Hasselbalch HC
    Ugeskr Laeger; 2004 Feb; 166(6):466-9. PubMed ID: 15045710
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.